ReviewEMBO reports2025
Cancer microbiota: a focus on tumor-resident bacteria.
Review in EMBO reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Microbial Systems Enhancing CAR-Based Therapies: A Synthetic Biology Paradigm for Next-Generation Cancer Immunotherapy.Current microbiology · 2025Pooled it
- Harnessing microfluidics for microbiology: from bacteria-host interactions to emerging cancer therapies.Communications biology · 2026Review
- Tumor Exposomics: A New Paradigm for Individualized Continuous Exposure Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Pathology-derived clinical micro-architectural diagnostics of tumour-microbiome interactions in colorectal cancer.Journal of translational medicine · 2026Article
- From Mechanism to Clinic: Engineered Bacteria-Nanomaterial Hybrid Systems for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Article
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Accumulating evidence highlights the presence of an intratumoral microbiota across various cancer types. Among all the microorganisms comprising the tumor-associated microbiota, tumor-resident bacteria (TRB) are increasingly recognized as critical regulators of cancer biology. Within tumor tissues, these microorganisms interact with various components of the tumor microenvironment (TME) and influence both tumor-promoting and tumor-suppressing pathways, underlying their dual role in cancer. Fully understanding the functional roles of TRB and their complex interactions with components of the TME requires the application of multimodal technologies. Developing strategies to modulate TRB-either by eradicating pathogenic populations or harnessing beneficial ones-holds great promise for advancing cancer treatment. In this review, we summarize the most recent insights into TRB. We discuss their possible origins and their implications on cancer biology, focusing on their roles in cancer development, metastasis establishment, immune modulation, and therapy response. Finally, we describe bacteria-based strategies and address the major challenges in detecting and analyzing these microbial communities in tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.